WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009135583) PHARMACEUTICAL COMPOSITION COMPRISING RIMEPORIDE FOR TREATING DISEASES ASSOCIATED WITH INSULIN RESISTANCE AND BETA-CELL DYSFUNCTION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/135583    International Application No.:    PCT/EP2009/002701
Publication Date: 12.11.2009 International Filing Date: 11.04.2009
IPC:
A61K 31/155 (2006.01), A61P 3/10 (2006.01)
Applicants: MERCK PATENT GMBH [DE/DE]; Frankfurter Strasse 250 64293 Darmstadt (DE) (For All Designated States Except US).
BEIER, Norbert [DE/DE]; (DE) (For US Only).
SCHOLZ, Wolfgang [DE/DE]; (DE) (For US Only).
BETZ, Ulrich [DE/DE]; (DE) (For US Only).
BRAENDLE, Marian [DE/DE]; (DE) (For US Only)
Inventors: BEIER, Norbert; (DE).
SCHOLZ, Wolfgang; (DE).
BETZ, Ulrich; (DE).
BRAENDLE, Marian; (DE)
Priority Data:
08008763.8 09.05.2008 EP
Title (EN) PHARMACEUTICAL COMPOSITION COMPRISING RIMEPORIDE FOR TREATING DISEASES ASSOCIATED WITH INSULIN RESISTANCE AND BETA-CELL DYSFUNCTION
(FR) COMPOSITION PHARMACEUTIQUE À BASE DE RIMÉPORIDE DESTINÉE AU TRAITEMENT DE MALADIES ASSOCIÉES À L'INSULINORÉSISTANCE ET À UN DYSFONCTIONNEMENT DES CELLULES BÊTA
Abstract: front page image
(EN)The invention relates to a pharmaceutical composition comprising as active ingredient an effective amount of 2-Methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the prophylaxis and therapy of Type Il diabetes mellitus, the Metabolic syndrome, diabetic nephropathy and/or neuropathy. Another object of the invention concerns the use of 2-Methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the enhancement of insulin sensitivity and the preservation or increase of β-cell compensation.
(FR)La présente invention concerne une composition pharmaceutique renfermant comme principe actif une quantité efficace de 2-méthyl-4,5-di- (méthylsulfonyl)- benzoyl-guanidine ou ses dérivés, et indiquée pour la prophylaxie et la thérapie du diabète de type II, le syndrome métabolique, ainsi que pour la néphropathie diabétique et/ou la neuropathie diabétique. Un autre objet de l’invention concerne l’utilisation de la 2-méthyl-4,5-di-(méthylsulfonyl)- benzoyl-guanidine ou de ses dérivés, pour l’amplification de la sensibilité à l’insuline et la conservation ou l’augmentation de la compensation des cellules β.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)